ARS Pharmaceuticals, Inc. (SPRY)
Data as of , from SEC Form 4 filings.
See up to 3 months of SPRY. The 7-day demo opens the 1M and 3M ranges and puts SPRY on your watchlist.
Start 7-day demoLatest SPRY insider trades
- Eric Karas - OfficerOpen-market sale$250K
Alexander A. Fitzpatrick - OfficerOpen-market sale
About ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
- SAN DIEGO, CA
- 200
- 2022
- XNAS
SPRY Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 2 | 2,038,661 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
SPRY insider transactions (Form 4)
6049 Form 4 filings on record, the earliest from Oct 10, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Donn Casale - Officer | Grant or award | Stock Option (right to buy) | 1,036,923 | $0.00 | - | |
| Margaret Ekins Smith - Officer | Grant or award | Stock Option (right to buy) | 1,001,738 | $0.00 | - | |
| Donn Casale - Officer | Grant or award | Stock Option (right to buy) | 898,456 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
 Rajeev Dadoo | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Pratik Shah | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Michael Kelly | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Saqib Islam | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
 Peter A. Thompson | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Brent L. Saunders | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Phillip M. Schneider | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Laura Shawver | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Eric Karas - Officer | Option exercise | Common Stock | 25,000 | $1.50 | $38K | |
| Eric Karas - Officer | Open-market sale | Common Stock | 25,000 | $10.00 | $250K | |
| Eric Karas - Officer | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Alexander A. Fitzpatrick - Officer | Open-market sale | Common Stock | 3,355 | $10.00 | $34K | |
| Justin Chakma - Officer | Option exercise | Common Stock | 30,000 | $0.84 | $25K | |
| Justin Chakma - Officer | Open-market sale | Common Stock | 30,000 | $8.91 footnote F1 | $267K | |
| Justin Chakma - Officer | Open-market sale | Common Stock | 136,380 | $8.86 footnote F2 | $1.21M | |
| Justin Chakma - Officer | Option exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| ||||||
| Pratik Shah | Gift | Common Stock | 250,000 | $0.00 | - | |
| Pratik Shah | Gift | Common Stock | 100,000 | $0.00 | - | |
 Brian Dorsey - Officer | Open-market sale | Common Stock | 21,828 | $8.71 footnote F2 | $190K | |
| Brian Dorsey - Officer | Option exercise | Stock Option (Right to Buy) | 21,828 | $0.00 | - | |
| Brian Dorsey - Officer | Option exercise | Common Stock | 21,828 | $0.64 | $14K | |
| ||||||
| Kathleen D. Scott - Officer | Option exercise | Common Stock | 12,500 | $1.50 | $19K | |
| Kathleen D. Scott - Officer | Open-market sale | Common Stock | 12,500 | $15.00 | $188K | |
| Kathleen D. Scott - Officer | Option exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | - | |
 Richard E. Lowenthal - Officer | Open-market sale | Common Stock | 50,000 | $14.49 | $724K | |
| Sarina Tanimoto - Officer | Open-market sale | Common Stock | 12,344 | $14.03 | $173K | |
| Sarina Tanimoto - Officer | Open-market sale | Common Stock | 37,656 | $14.09 | $531K | |
| Eric Karas - Officer | Option exercise | Common Stock | 15,000 | $1.50 | $23K | |
| Eric Karas - Officer | Open-market sale | Common Stock | 15,000 | $16.99 | $255K | |
| Eric Karas - Officer | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| James E. Flynn - 10% Owner | Open-market sale | Class A Common Stock | 370,075 | $18.46 | $6.83M | |
| James E. Flynn - 10% Owner | Open-market sale | Class A Common Stock | 370,074 | $18.46 | $6.83M | |
| Brent L. Saunders | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Phillip M. Schneider | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Brent L. Saunders | Option exercise | Common Stock | 120,000 | $1.01 | $121K | |
| Brent L. Saunders | Open-market sale | Common Stock | 120,000 | $14.25 | $1.71M | |
| Brent L. Saunders | Option exercise | Stock Option (Right to Buy) | 120,000 | $0.00 | - | |
| Sarina Tanimoto - Officer | Open-market sale | Common Stock | 50,000 | $11.67 | $584K | |
| Sarina Tanimoto - Officer | Open-market sale | Common Stock | 50,000 | $11.67 | $584K | |
| Richard E. Lowenthal - Officer | Open-market sale | Common Stock | 50,000 | $11.67 | $584K | |
| Richard E. Lowenthal - Officer | Open-market sale | Common Stock | 50,000 | $11.67 | $584K | |
| Justin Chakma - Officer | Option exercise | Common Stock | 117,333 | $0.84 | $99K | |
| Justin Chakma - Officer | Open-market sale | Common Stock | 117,333 | $12.27 | $1.44M | |
| Justin Chakma - Officer | Option exercise | Common Stock | 27,272 | $1.44 | $39K | |
| Justin Chakma - Officer | Open-market sale | Common Stock | 27,272 | $12.06 | $329K | |
| Justin Chakma - Officer | Option exercise | Stock Option (Right to Buy) | 117,333 | $0.00 | - | |
| Justin Chakma - Officer | Option exercise | Stock Option (Right to Buy) | 27,272 | $0.00 | - | |
| Brian Dorsey - Officer | Option exercise | Common Stock | 15,000 | $0.64 | $10K | |
| Brian Dorsey - Officer | Open-market sale | Common Stock | 15,000 | $12.43 | $186K | |
| Brian Dorsey - Officer | Option exercise | Common Stock | 25,000 | $0.64 | $16K | |
| Brian Dorsey - Officer | Open-market sale | Common Stock | 25,000 | $12.30 | $307K | |
| Brian Dorsey - Officer | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Brian Dorsey - Officer | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Justin Chakma - Officer | Option exercise | Common Stock | 50,000 | $0.84 | $42K | |
| Justin Chakma - Officer | Open-market sale | Common Stock | 50,000 | $13.15 | $658K | |
| Justin Chakma - Officer | Option exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
Recent SPRY Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| ERIC KARAS | Officer | 100,000 | $426K | View on EDGAR | |
| ERIC KARAS | Officer | 100,000 |
SPRY insider trading FAQ
What is the latest insider trade for SPRY?
ARS Pharmaceuticals, Inc. (SPRY) had 2 insider filings in the last 90 days, with the most recent on 2026-10-05. The full record for SPRY runs to 49 Form 4 filings, the earliest from 2024-10-10. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SPRY stock?
No insider purchases of SPRY were filed in the last 90 days.
How many insiders are selling SPRY stock?
No insider sales of SPRY were filed in the last 90 days. 71 sales are on record for this company.
Where can I see SPRY SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SPRY Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Donn Casale view on EDGAR
- - Margaret Ekins Smith view on EDGAR
- - Donn Casale view on EDGAR
- - RA CAPITAL MANAGEMENT, L.P. view on EDGAR
- - Rajeev Dadoo view on EDGAR
- - Pratik Shah view on EDGAR
- - Michael Kelly view on EDGAR
- - Saqib Islam view on EDGAR
- - Peter A. Thompson view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where SPRY's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SPRY with a 7-day demo
- SPRY on your watchlist
- Every SPRY Form 4 filing on record
- Up to 3 months of SPRY price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
